Talin O Haritunians from Los Angeles, CA, age 51

Methods Of Using Znf365 Genetic Variants To Diagnose Crohn's Disease
view source
US Patent:

20130012602, Jan 10, 2013
Filed:

Jan 13, 2011
Appl. No.:

13/521199
Inventors:

Talin Haritunians - Los Angeles CA, US
Jerome I. Rotter - Los Angeles CA, US
Kent D. Taylor - Ventura CA, US
Stephan R. Targan - Santa Monica CA, US
Assignee:

CEDARS-SINAI MEDICAL CENTER - Los Angeles CA
International Classification:

C12Q 1/68
G01N 27/447
A61P 1/00
C40B 30/04
A61K 35/00
US Classification:

514789, 435 611, 506 9, 204461
Abstract:

The present invention relates to prognosing, diagnosing and treating of Crohn's disease. The invention also provides prognosis, diagnosis, and treatment that are based upon the presence of one or more genetic risk factors at the ZNF365 genetic locus

Methods Of Diagnosing Ulcerative Colitis And Crohn's Disease
view source
US Patent:

20140017711, Jan 16, 2014
Filed:

Mar 26, 2012
Appl. No.:

14/007381
Inventors:

Kent D. Taylor - Ventura CA, US
Dermot P. McGovern - Los Angeles CA, US
Jerome I. Rotter - Los Angeles CA, US
Stephan R. Targan - Santa Monica CA, US
Talin Haritunians - Los Angeles CA, US
Assignee:

CEDARS-SINAI MEDICAL CENTER - Los Angeles CA
International Classification:

G01N 33/68
US Classification:

435 792
Abstract:

The present invention relates to methods of prognosing inflammatory bowel disease (IBD) in an individual by determining the presence of at least one risk genetic variant and/or at least one risk serological marker. In one embodiment, the presence of risk serological marker ANCA is indicative of an aggressive form of ulcerative colitis. In another embodiment, the present invention relates to methods of diagnosing a Crohn's disease subtype in an individual, where the presence of risk variants and serological markers I2, OmpC and/or Cbir1 are indicative of the Crohn's disease subtype.

Methods Of Predicting Medically Refractive Ulcerative Colitis (Mr-Uc) Requiring Colectomy
view source
US Patent:

20120053131, Mar 1, 2012
Filed:

Dec 24, 2009
Appl. No.:

13/140874
Inventors:

Jerome I. Rotter - Los Angeles CA, US
Kent D. Taylor - Ventura CA, US
Stephan R. Targan - Santa Monica CA, US
Talin Haritunians - Encino CA, US
Dermot P. McGovern - Los Angeles CA, US
Xiuqing Guo - Santa Monica CA, US
Assignee:

CEDARS-SINAI MEDICAL CENTER - Los Angeles CA
International Classification:

A61K 38/12
A61K 31/56
C40B 40/06
A61B 17/00
C12Q 1/68
C40B 30/04
US Classification:

514 211, 435 611, 506 9, 506 16, 128898, 514179
Abstract:

Disclosed are methods of predicting the development of medically refractory ulcerative colitis (MR-UC) in a patient In one embodiment, disclosed is a method of prognosing ulcerative colitis in an individual by determining the presence or absence of one or more risk variants, where the presence of one or more risk variants is indicative of a severe and/or aggressive form of ulcerative colitis. In another embodiment, the severe form of ulcerative colitis is indicative of MR-UC.

Predicting Extraintestinal Manifestations Of Inflammatory Bowel Disease
view source
US Patent:

20220290241, Sep 15, 2022
Filed:

May 26, 2022
Appl. No.:

17/825580
Inventors:

- Los Angeles CA, US
Michelle KHROM - Northridge CA, US
Talin HARITUNIANS - Los Angeles CA, US
International Classification:

C12Q 1/6883
A61K 45/06
A61P 37/06
A61K 31/573
C07K 16/24
C07K 16/28
Abstract:

Provided are methods, systems, and kits for identifying a patient who has or has a likelihood of developing an extra-intestinal manifestation of inflammatory bowel disease.

Methods Of Predicting Medically Refractive Ulcerative Colitis (Mruc) Requiring Colectomy
view source
US Patent:

20190218616, Jul 18, 2019
Filed:

Mar 27, 2019
Appl. No.:

16/366894
Inventors:

- Los Angeles CA, US
Kent D. Taylor - Ventura CA, US
Stephan R. Targan - Santa Monica CA, US
Talin Haritunians - Encino CA, US
Dermot P. McGovern - Los Angeles CA, US
Xiuqing Guo - Santa Monica CA, US
Philip Fleshner - Los Angeles CA, US
International Classification:

C12Q 1/6883
Abstract:

The present invention relates to methods of predicting the risk for colectomy in a subject with mrUC, by determining the presence or absence of one or more mrUC risk variants. Other embodiment, relate to methods of treating mrUC in a subject and a kit for prognostic use.

Methods Of Predicting Medically Refractive Ulcerative Colitis (Mruc) Requiring Colectomy
view source
US Patent:

20170044615, Feb 16, 2017
Filed:

Oct 31, 2016
Appl. No.:

15/338782
Inventors:

- Los Angeles CA, US
Kent D. Taylor - Ventura CA, US
Stephan R. Targan - Santa Monica CA, US
Talin Haritunians - Encino CA, US
Dermot P. McGovern - Los Angeles CA, US
Xiuqing Guo - Santa Monica CA, US
Philip Fleshner - Los Angeles CA, US
Assignee:

Cedars-Sinai Medical Center - Los Angeles CA
International Classification:

C12Q 1/68
Abstract:

The present invention relates to methods of predicting the risk for colectomy in a subject with mrUC, by determining the presence or absence of one or more mrUC risk variants. Other embodiment, relate to methods of treating mrUC in a subject and a kit for prognostic use.

Methods Of Diagnosing And Treating Inflammatory Bowel Disease
view source
US Patent:

20150376707, Dec 31, 2015
Filed:

Sep 8, 2015
Appl. No.:

14/847705
Inventors:

- Los Angeles CA, US
Jerome I. Rotter - Los Angeles CA, US
Kent D. Taylor - Ventura CA, US
Marla C. Dubinsky - Los Angeles CA, US
Dermot P. McGovern - Los Angeles CA, US
Talin Haritunians - Los Angeles CA, US
Xiuqing Guo - Santa Monica CA, US
Rebecca Gonsky - Los Angeles CA, US
Richard Deem - Azusa CA, US
Assignee:

CEDARS-SINAI MEDICAL CENTER - Los Angeles CA
International Classification:

C12Q 1/68
Abstract:

The present invention also provides various methods, kits and compositions for diagnosing, prognosing, and treating various conditions including but not limited to inflammatory bowel diseases, such as ulcerative colitis and Crohn's disease. Also, the present invention provides various methods, kits and compositions for determining susceptibility to or a low probability of various conditions including but not limited to inflammatory bowel diseases, such as ulcerative colitis and Crohn's disease. These methods, kits and compositions may involve detecting risk/protective variants or haplotypes, serological markers, increased or decreased gene methylation, and increased or decreased cytokine secretion.

Talin O Haritunians